← Leaderboards
Daniel G. Jay
Tufts University Boston
$9,101,895
Attributed
$9,101,895
Total exposure
9
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $934.2K · FY2005–22$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$9,101,895 · 9
By mechanism
R01$6,155,102 · 5
R33$2,498,063 · 2
R21$448,730 · 2
Top collaborators
No co-investigators on record.
Most similar at Tufts University Boston
Same institution · by research overlap
- Naomi Rosenberg$5,769,212
- Brent H. Cochran$3,266,124
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsProteinsMalignant NeoplasmsBaseCellsIn VivoCancer CellLasersTumorReagentCancer TherapyLeadLaboratory MouseProtein FunctionMolecular ChaperonesExtracellular MatrixPharmacologic SubstanceClinical TrialsChromophoreAnimal ModelExtracellularDrug KineticsCessation Of LifeNeoplasm Metastasis
Grant awards (29)
Inhibiting extracellular Hsp90 to reduce breast cancer metastasis$119,582
R01 · FY2022 · CA · contact PI
Inhibiting extracellular Hsp90 to reduce breast cancer metastasis$1
R01 · FY2021 · CA · contact PI
Inhibiting extracellular Hsp90 to reduce breast cancer metastasis$255,415
R01 · FY2020 · CA · contact PI
Inhibiting extracellular Hsp90 to reduce breast cancer metastasis$366,114
R01 · FY2019 · CA · contact PI
Inhibiting extracellular Hsp90 to reduce breast cancer metastasis$377,438
R01 · FY2018 · CA · contact PI
Inhibiting extracellular Hsp90 to reduce breast cancer metastasis$377,438
R01 · FY2017 · CA · contact PI
Inhibiting extracellular Hsp90 to reduce breast cancer metastasis$377,438
R01 · FY2016 · CA · contact PI
KillerRed Assisted Mutagenesis to discover cancer drug resistance genes$321,833
R01 · FY2013 · CA · contact PI
KillerRed Assisted Mutagenesis to discover cancer drug resistance genes$342,375
R01 · FY2012 · CA · contact PI
PROTEOME SIGNATURES AND TARGET VALIDATION IN LYMPHOMAS$585,012
R33 · FY2009 · CA · contact PI
INHIBITING SURFACE HSP90 TO LIMIT METASTASIS$275,562
R01 · FY2009 · CA · contact PI
PROTEOME SIGNATURES AND TARGET VALIDATION IN LYMPHOMAS$658,595
R33 · FY2008 · CA · contact PI
INHIBITING SURFACE HSP90 TO LIMIT METASTASIS$275,562
R01 · FY2008 · CA · contact PI
INHIBITING SURFACE HSP90 TO LIMIT METASTASIS$275,562
R01 · FY2007 · CA · contact PI
INHIBITING SURFACE HSP90 TO LIMIT METASTASIS$283,792
R01 · FY2006 · CA · contact PI
INHIBITING SURFACE HSP90 TO LIMIT METASTASIS$290,621
R01 · FY2005 · CA
PROTEOME SIGNATURES AND TARGET VALIDATION IN LYMPHOMAS$139,884
R21 · FY2005 · CA
PROTEOME SIGNATURES AND TARGET VALIDATION IN LYMPHOMAS$140,124
R21 · FY2004 · CA
ROLE OF MYOSIN ISOFORMS IN NERVE GROWTH CONE MOTILITY$340,617
R01 · FY2003 · NS
HIGH THROUGHPUT CALI FOR TARGET VALIDATION IN METASTASIS$635,173
R33 · FY2002 · CA
ROLE OF MYOSIN ISOFORMS IN NERVE GROWTH CONE MOTILITY$330,693
R01 · FY2002 · NS
REPULSIVE CUES AND THE DEVELOPING VISUAL SYSTEM$326,988
R01 · FY2002 · EY
HIGH THROUGHPUT CALI FOR TARGET VALIDATION IN METASTASIS$619,283
R33 · FY2001 · CA
ROLE OF MYOSIN ISOFORMS IN NERVE GROWTH CONE MOTILITY$321,063
R01 · FY2001 · NS
REPULSIVE CUES AND THE DEVELOPING VISUAL SYSTEM$283,483
R01 · FY2001 · EY
ROLE OF MYOSIN ISOFORMS IN NERVE GROWTH CONE MOTILITY$289,535
R01 · FY2000 · NS
REPULSIVE CUES AND THE DEVELOPING VISUAL SYSTEM$273,990
R01 · FY2000 · EY
HIGH THROUGHPUT CALI FOR TARGET VALIDATION IN METASTASIS$168,722
R21 · FY2000 · CA
ROLE OF MYOSIN ISOFORMS IN NERVE GROWTH CONE MOTILITY$50,000
R01 · FY2000 · NS